IGF-1 ELISA Test: Principle, Protocol, Samples, and Applications

```

The IGF-1 ELISA test is a widely used immunoassay for quantitative measurement of insulin-like growth factor 1 in serum, plasma, and other biological samples. As a key biomarker of growth hormone activity, IGF-1 measurement plays an essential role in diagnosing growth disorders, acromegaly, and metabolic conditions. This article provides a comprehensive technical overview of the IGF-1 ELISA test, including its principle, sample requirements, methodology, and clinical applications.

Technical Overview

Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid polypeptide hormone with a molecular weight of approximately 7.6 kDa. It is produced primarily by the liver under the stimulation of growth hormone (GH) and mediates most of the growth-promoting effects of GH. Because IGF-1 secretion is GH-dependent and its serum levels remain relatively stable throughout the day, it serves as a more reliable indicator of GH status than random GH measurements.

The IGF-1 ELISA test is typically based on the sandwich enzyme-linked immunosorbent assay format. A capture antibody specific to human IGF-1 is pre-coated onto a microplate. Standards and samples are added, and any IGF-1 present binds to the immobilized antibody. A detection antibody conjugated with horseradish peroxidase (HRP) then binds to a different epitope of IGF-1, forming an antibody-antigen-antibody sandwich complex. After the addition of a chromogenic substrate such as TMB (3,3',5,5'-tetramethylbenzidine), a colorimetric reaction develops in proportion to the IGF-1 concentration. The reaction is terminated with an acidic stop solution, and absorbance is measured at 450 nm using a microplate reader. The IGF-1 concentration in samples is then calculated from a standard curve generated with known concentrations.

A critical technical consideration in IGF-1 measurement is that circulating IGF-1 exists predominantly in complexes with high-affinity IGF-binding proteins (IGFBPs), which account for more than 99% of total serum IGF-1. To ensure accurate quantification, most ELISA kits incorporate a sample pretreatment step, such as acid-ethanol extraction or the use of IGFBP-blocking reagents, to release IGF-1 from these binding proteins before analysis.

Testing Samples

Serum

Serum is the most commonly used sample type for IGF-1 ELISA testing. Venous blood is collected using a standard serum separator tube and allowed to clot for 30 minutes at room temperature before centrifugation at 1,000-2,000 x g for 15 minutes. The separated serum should be assayed immediately or stored at -20°C or below for long-term preservation. Repeated freeze-thaw cycles should be avoided to prevent protein degradation.

Plasma

Plasma collected with EDTA or heparin anticoagulants is also acceptable for IGF-1 measurement. Blood is collected into anticoagulant tubes, gently inverted to mix, and centrifuged within 30 minutes of collection at 1,000-2,000 x g for 15 minutes at 4°C. The plasma supernatant is carefully transferred to a clean tube without disturbing the cell pellet.

Cell Culture Supernatant

For in vitro research applications, cell culture media can be analyzed to quantify IGF-1 secreted by cultured hepatocytes, fibroblasts, or other cell types. Samples should be centrifuged to remove cellular debris and particulates before assay. Media containing high protein concentrations may require dilution with the assay diluent provided in the kit.

Tissue Homogenates

Tissue samples can be homogenized in an appropriate PBS-based lysis buffer containing protease inhibitors. The homogenate is centrifuged at high speed to remove debris, and the clarified supernatant is collected for analysis. Total protein concentration of the lysate should be determined separately to normalize IGF-1 expression results.

Testing Items

The IGF-1 ELISA test primarily measures the following analytes:

• Total IGF-1 concentration in serum or plasma, expressed in ng/mL, following dissociation from IGFBPs
• Free IGF-1, the biologically active unbound fraction, measured using specialized assays that avoid sample pretreatment
• IGF-1 levels in research samples for preclinical and mechanistic studies
• Serial IGF-1 measurements for monitoring treatment response in patients receiving recombinant human GH therapy

Reference ranges for serum IGF-1 vary significantly with age, sex, and pubertal status. Levels are lowest in infancy and old age, peak during adolescence, and gradually decline with advancing age. Interpretation of results should always be performed against age- and sex-matched reference intervals established by the testing laboratory or kit manufacturer.

Testing Methods

The standard IGF-1 ELISA procedure follows a typical sandwich immunoassay workflow with slight variations among different manufacturers. The general protocol is described below:

• Bring all reagents, standards, and samples to room temperature (18-25°C) before starting the assay
• Prepare serial dilutions of the IGF-1 standard to generate a multi-point standard curve
• Pretreat samples according to kit instructions to dissociate IGF-1 from binding proteins, typically using an acidification-neutralization procedure or IGFBP-blocking solution
• Add standards and samples to the antibody-coated wells in duplicate and incubate for the specified time, usually 1-2 hours at 37°C
• Wash the plate 3-5 times with wash buffer to remove unbound material
• Add the HRP-conjugated detection antibody and incubate
• Wash the plate thoroughly to remove excess conjugate
• Add TMB substrate solution and incubate in the dark for 10-20 minutes until color develops
• Add stop solution and measure absorbance at 450 nm within 5 minutes using a microplate reader
• Calculate sample concentrations using a four-parameter logistic (4-PL) curve fit of the standard curve

Assay performance characteristics typically include a detection limit below 1 ng/mL, an intra-assay coefficient of variation (CV) below 10%, and an inter-assay CV below 15%. Dilution linearity and spike-recovery experiments should be performed during method validation to confirm assay accuracy across the measuring range.

Applications

The IGF-1 ELISA test has broad applications in both clinical diagnostics and biomedical research:

• Diagnosis of growth hormone deficiency in children with short stature, where low IGF-1 levels support impaired GH secretion
• Screening and diagnosis of acromegaly and gigantism, conditions characterized by GH hypersecretion and elevated IGF-1 levels
• Monitoring of treatment response in patients receiving somatostatin analogs, GH receptor antagonists, or surgery for acromegaly
• Assessment of GH insensitivity syndromes such as Laron syndrome, where GH levels are high but IGF-1 is low
• Evaluation of nutritional status and hepatic function, as malnutrition and liver disease suppress IGF-1 production
• Research into cancer biology, as IGF-1 signaling is implicated in tumor proliferation and progression
• Studies of aging, metabolism, and endocrine regulation in clinical and preclinical research settings
• Detection of GH abuse in anti-doping programs, since exogenous GH administration elevates IGF-1 concentrations

FAQ

Why does the IGF-1 ELISA require sample pretreatment?

Most circulating IGF-1 is bound to IGFBPs, which can interfere with antibody binding and lead to inaccurate results. Acid-ethanol extraction or IGFBP-blocking reagents release IGF-1 from these complexes, allowing accurate measurement of total IGF-1.

How should samples be stored before testing?

Samples can be stored at 2-8°C for up to 48 hours. For longer storage, keep samples frozen at -20°C or -80°C. Avoid more than two freeze-thaw cycles, and always mix thawed samples gently before analysis.

Is fasting required before IGF-1 testing?

Unlike GH, which fluctuates dramatically with meals and stress, IGF-1 levels are relatively stable throughout the day. Fasting is generally not required, although some laboratories recommend morning collection for consistency.

What factors can affect IGF-1 test results?

Age, sex, pubertal stage, nutritional status, hepatic function, renal function, thyroid status, pregnancy, diabetes, and certain medications can all influence IGF-1 concentrations. These factors must be considered during result interpretation.

Can a single IGF-1 measurement confirm a diagnosis?

No. IGF-1 results should be interpreted alongside clinical presentation, GH stimulation or suppression tests, imaging studies, and age- and sex-matched reference ranges. Abnormal IGF-1 values typically require confirmatory dynamic testing.

What is the difference between IGF-1 and GH testing?

GH is secreted in a pulsatile manner, making random GH measurements unreliable. IGF-1 reflects integrated GH activity over time with minimal diurnal variation, making it a superior first-line screening marker for GH-related disorders.

```